New Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis

Phase

N/A

Condition

Scar Tissue

Myasthenia Gravis (Chronic Weakness)

Amyotrophic Lateral Sclerosis (Als)

Treatment

Muscular MRI

Brain MRI

Electrophysiological exam

Clinical Study ID

NCT04691011

2020-50

Ages > 18
All Genders
Accepts Healthy Volunteers

Study Summary

Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Our project aims to find new biomarkers in MRI at three levels: cerebral, medullary and muscular. These markers could allow an earlier diagnosis of the disease by showing more specific lesions of ALS and to quantify these lesions to measure the progression of the disease. This study will use advanced Magnetic Resonance Imaging (MRI) techniques High field (3T) and very high field (7T) MRI. Results from neurological and electrophysiological tests will be compared to the MRI. Subjects will be recruited from ALS center of Marseille, France. MRI will be done on ALS patients at baseline, at 3 month and at 6 month intervals.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients will be adults with a diagnosis of ALS.
Healthy controls will also be recruited and will be age- and gender-matched topatients.
Patients able to undergo a brain MRI for approximately an hour.

Exclusion

Exclusion Criteria:

Subjects with other psychiatric or CNS or PNS diseases.
Subjects ineligible for MRI investigation due to a pacemaker or other metallicforeign body, or significant claustrophobia that could affect the ability to have anMRI scan.

Study Design